Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Alcohol intake and stomach cancer risk in Japan: A pooled analysis of six cohort studies.
Tamura T, Wakai K, Lin Y, Tamakoshi A, Utada M, Ozasa K, Sugawara Y, Tsuji I, Ono A, Sawada N, Tsugane S, Ito H, Nagata C, Kitamura T, Naito M, Tanaka K, Shimazu T, Mizoue T, Matsuo K, Inoue M; Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan. Tamura T, et al. Cancer Sci. 2022 Jan;113(1):261-276. doi: 10.1111/cas.15172. Epub 2021 Nov 28. Cancer Sci. 2022. PMID: 34689390 Free PMC article.
Body mass index and esophageal and gastric cancer: A pooled analysis of 10 population-based cohort studies in Japan.
Koyanagi YN, Matsuo K, Ito H, Wang C, Tamakoshi A, Sugawara Y, Tsuji I, Ono A, Tsugane S, Sawada N, Wada K, Nagata C, Takeuchi T, Kitamura T, Utada M, Sakata R, Mizoue T, Abe SK, Inoue M; Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan. Koyanagi YN, et al. Cancer Sci. 2023 Jul;114(7):2961-2972. doi: 10.1111/cas.15805. Epub 2023 May 10. Cancer Sci. 2023. PMID: 37013939 Free PMC article.
Active and passive smoking and breast cancer in Japan: a pooled analysis of nine population-based cohort studies.
Wada K, Nagata C, Utada M, Sakata R, Kimura T, Tamakoshi A, Sugawara Y, Tsuji I, Sato R, Sawada N, Tsugane S, Oze I, Ito H, Kitamura T, Koyanagi YN, Lin Y, Matsuo K, Abe SK, Inoue M; Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan. Wada K, et al. Int J Epidemiol. 2024 Apr 11;53(3):dyae047. doi: 10.1093/ije/dyae047. Int J Epidemiol. 2024. PMID: 38604675
Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).
Sakata Y, Saito G, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Junji U, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: suzuki h. Lung Cancer. 2023 Dec;186:107426. doi: 10.1016/j.lungcan.2023.107426. Epub 2023 Nov 19. Lung Cancer. 2023. PMID: 37992594
Corrigendum to "Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426].
Sakata Y, Saito G, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Junji U, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: suzuki h. Lung Cancer. 2024 Feb;188:107450. doi: 10.1016/j.lungcan.2023.107450. Epub 2023 Dec 30. Lung Cancer. 2024. PMID: 38160082 No abstract available.
Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005).
Kawachi H, Tamiya M, Oya Y, Saito G, Taniguchi Y, Matsumoto H, Sato Y, Otsuki T, Suzuki H, Fukuda Y, Tanaka S, Tsukita Y, Uchida J, Sakata Y, Nakatani Y, Shibaki R, Arai D, Okada A, Hara S, Takayama K, Nishino K. Kawachi H, et al. Among authors: suzuki h. Clin Lung Cancer. 2024 Nov;25(7):643-652.e4. doi: 10.1016/j.cllc.2024.07.014. Epub 2024 Jul 25. Clin Lung Cancer. 2024. PMID: 39138106
Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study.
Imaji M, Fujimoto D, Sato Y, Sakata Y, Oya Y, Tamiya M, Suzuki H, Ikeda H, Kijima T, Matsumoto H, Kanazu M, Hino A, Inaba M, Tsukita Y, Arai D, Maruyama H, Hara S, Tsumura S, Kobe H, Sumikawa H, Sakata S, Yamamoto N. Imaji M, et al. Among authors: suzuki h. Eur J Cancer. 2023 Jan;179:15-24. doi: 10.1016/j.ejca.2022.10.029. Epub 2022 Nov 12. Eur J Cancer. 2023. PMID: 36470023
15,284 results
You have reached the last available page of results. Please see the User Guide for more information.